The Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) is a consortium that brings together scientists from 14 countries to shorten and simplify treatment for TB, through clinical trials and capacity development. UCL-TB PanACEA page; PanACEA Consortium page; EDCTP news
Research to Improve Detection and Treatment of Latent TB Infection (Oct 2018-Sep 2023) IGH RID-TB page
A randomised trial of shortening treatment for minimal (non-severe) tuberculosis (TB) in African and Indian children (July 2016-Oct 2020). Start of trial announcement, MRC-CTU study page, Trial result announcement
SimpliciTB is a phase 3 open-label partially randomised clinical trial evaluating the efficacy, safety and tolerability of a novel and potentially shorter drug regimen (BPaMZ) for patients with drug-sensitive (DS) and drug-resistant (MDR-) pulmonary tuberculosis (2018-2022). MRC-CTU study page; TB Alliance page.
STREAM Stage 2
A phase III cluster randomised placebo‐controlled trial to assess the efficacy of preventive therapy in child contacts of multidrug‐resistant tuberculosis (2017-2020). MRC-CTU study page; UKRI Project page; WITS press release
TRUNCATE-TB (Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis) is trying to speed up treatment of fully drug-sensitive TB (Duration: Sept 2013-2022) MRC-CTU study page; SPRINT-TB page;
ZeNix is a phase 3 partially-blinded, randomised trial assessing the safety and efficacy of reducing the amount of Linezolid in the Bedaquiline/Pretomanid/Linezolid (BPaL) regimen for drug-resistant TB (Nov 2017-2022). TB Alliance page; MRC-CTU page